Head & Neck/Thyroid Cancers
Conference Coverage
Germline testing in advanced cancer can lead to targeted treatment
In a study of nearly 12,000 cancer patients, 7%-9% of patients had targetable germline alterations.
News
Patient-focused precautions, testing help blunt pandemic effects on heme-onc unit
Multiple factors helped keep the anticipated COVID-19 surge manageable at the hematologic oncology service of Levine Cancer Institute.
Conference Coverage
ASCO goes ahead online, as conference center is used as hospital
News
FDA approves selpercatinib for lung and thyroid RET tumors
News
COVID-19 death rate was twice as high in cancer patients in NYC study
The overall case fatality rate was 28% for cancer patients with COVID-19 and 14% for noncancer COVID-19 patients.
News
Excess cancer deaths predicted as care is disrupted by COVID-19
Conference Coverage
Antitumor treatment may increase risk of severe events in COVID-19 patients
Article
ASCO panel outlines cancer care challenges during COVID-19 pandemic
Article
Will coronavirus restrictions lead to more advanced cancers?
News
European cancer centers restructure care in the era of COVID-19
